Recursion inks second deal this week, this one with Roche

7 December 2021
roche_night_large

Deal hungry Recursion Pharmaceuticals (Nasdaq: RXRX) signed a second deal this week, entering into a collaboration with Swiss giant Roche (ROG: SIX) and its Genentech subsidiary, to more rapidly identify novel targets and advance medicines in key areas of neuroscience as well as in an oncology indication.

The news pushed Recursion’s shares up 8.3% to $20.01 by mid-morning, adding to the boost the stock had yesterday on the deal with Germany’s Bayer (BAYN: DE).

The collaboration will leverage the US digital biotech’s Recursion Operating System (OS), an integrated, multi-faceted system for generating, analyzing and deriving insight from massive proprietary biological and chemical datasets. The OS, which brings together wet-lab and dry-lab biology at scale to further industrialize and digitize drug discovery, will be deployed to phenomically capture chemical and genetic perturbations in neuroscience-related cell types and select cancer cell lines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology